Biocept provides update on covid-19 testing with more than 250,000 samples received

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its covid-19 testing with more than 250,000 samples received to date for processing through its rt-pcr technology at its clia-certified, cap-accredited, high-complexity molecular laboratory. “we continue to serve our community during the pandemic with this important testing and have received nearly
BIOC Ratings Summary
BIOC Quant Ranking